[1]
|
De Nardo, W., Miotto, P.M., Bayliss, J., et al. (2022) Proteomic Analysis Reveals Exercise Training Induced Remodel-ling of Hepatokine Secretion and Uncovers Syndecan-4 as a Regulator of Hepatic Lipid Metabolism. Molecular Metabo-lism, 60, Article ID: 101491. https://doi.org/10.1016/j.molmet.2022.101491
|
[2]
|
Warner, H., Wu, Y. and Wagner, W.D. (2021) Syndecan-4 Functionalization of Tissue Regeneration Scaffolds Improves Interaction with Endothelial Pro-genitor Cells. Regenerative Biomaterials, 8, rbab070.
https://doi.org/10.1093/rb/rbab070
|
[3]
|
Arokiasamy, S., Balderstone, M.J.M., De Rossi, G. and Whiteford, J.R. (2020) Syndecan-3 in Inflammation and Angiogenesis. Frontiers in Immunology, 10, Article No. 3031. https://doi.org/10.3389/fimmu.2019.03031
|
[4]
|
Lunde, I.G., Herum, K.M., Carlson, C.C. and Christensen, G. (2016) Syndecans in Heart Fibrosis. Cell and Tissue Research, 365, 539-552. https://doi.org/10.1007/s00441-016-2454-2
|
[5]
|
Christensen, G., Herum, K.M. and Lunde, I.G. (2019) Sweet, Yet Underappreciated: Proteoglycans and Extracellular Matrix Remodeling in Heart Disease. Matrix Biology, 75-76, 286-299. https://doi.org/10.1016/j.matbio.2018.01.001
|
[6]
|
Schlömmer, C., Brandtner, A. and Bachler, M. (2021) An-tithrombin and Its Role in Host Defense and Inflammation. International Journal of Molecular Sciences, 22, Article No. 4283. https://doi.org/10.3390/ijms22084283
|
[7]
|
Agere, S.A., Kim, E.Y., Akhtar, N. and Ahmed, S. (2018) Syndecans in Chronic Inflammatory and Autoimmune Diseases: Pathological Insights and Therapeutic Opportunities. Journal of Cellular Physiology, 233, 6346-6358.
https://doi.org/10.1002/jcp.26388
|
[8]
|
Hurysz, B. and Bottini, N. (2022) Emerging Proteoglycans and Proteogly-can-Targeted Therapies in Rheumatoid Arthritis. American Journal of Physiology-Cell Physiology, 322, C1061-C1067. https://doi.org/10.1152/ajpcell.00086.2022
|
[9]
|
Gondelaud, F. and Ricard-Blum, S. (2019) Structures and Interac-tions of Syndecans. FEBS Journal, 286, 2994-3007.
https://doi.org/10.1111/febs.14828
|
[10]
|
Scott, L.E., Weinberg, S.H. and Lemmon, C.A. (2019) Mechanochemical Signaling of the Extracellular Matrix in Epithelial-Mesenchymal Transition. Frontiers in Cell and Developmental Biology, 7, Article No. 135.
https://doi.org/10.3389/fcell.2019.00135
|
[11]
|
Kalluri, R. and Weinberg, R.A. (2009) The Basics of Epitheli-al-Mesenchymal Transition. Journal of Clinical Investigation, 119, 1420-1428. https://doi.org/10.1172/JCI39104
|
[12]
|
Couchman, J.R. (2021) Syndecan-1 (CD138), Carcinomas and EMT. In-ternational Journal of Molecular Sciences, 22, Article No. 4227. https://doi.org/10.3390/ijms22084227
|
[13]
|
Sun, D., Mcalmon, K.R., Davies, J.A., Bernfield, M. and Hay, E.D. (1998) Simultaneous Loss of Expression of Syndecan-1 and E-Cadherin in the Embryonic Palate during Epithelial-Mesenchymal Transformation. The International Journal of Developmental Biology, 42, 733-736.
|
[14]
|
Szatmári, T. and Dobra, K. (2013) The Role of Syndecan-1 in Cellular Sig-naling and Its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors. Frontiers in Oncology, 3, Article No. 310.
https://doi.org/10.3389/fonc.2013.00310
|
[15]
|
Handra-Luca, A. (2020) Syndecan-1 in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 1272, 39-53. https://doi.org/10.1007/978-3-030-48457-6_3
|
[16]
|
Ahmed Haji Omar, A., Haglund, C., Virolainen, S., et al. (2013) Epithelial and Stromal Syndecan-1 and -2 Are Distinctly Expressed in Oral- and Cutaneous Squamous Cell Carcinomas. Journal of Oral Pathology & Medicine, 42, 389-395. https://doi.org/10.1111/jop.12025
|
[17]
|
Shetty, P.K., Gonsalves, N., Desai, D., et al. (2022) Expression of Syndecan-1 in Different Grades of Oral Squamous Cell Carcinoma: An Immunohistochemical Study. Journal of Cancer Research and Therapeutics, 18, S191-S196.
https://doi.org/10.4103/jcrt.JCRT_1715_20
|
[18]
|
Pulkkinen, J.O., Penttinen, M., Jalkanen, M., Klemi, P. and Grénman, R. (1997) Syndecan-1: A New Prognostic Marker in Laryngeal Cancer. Acta Oto-Laryngologica, 117, 312-315. https://doi.org/10.3109/00016489709117794
|
[19]
|
Hu, X.F., Yao, J., Gao, S.G., Yang, Y.T., Peng, X.Q. and Feng, X.S. (2014) Midkine and Syndecan-1 Levels Correlate with the Progression of Malignant Gastric Cardiac Adenocarcinoma. Molecular Medicine Reports, 10, 1409-1415.
https://doi.org/10.3892/mmr.2014.2369
|
[20]
|
Wiksten, J.P., Lundin, J., Nordling, S., et al. (2001) Epithelial and Stromal Syndecan-1 Expression as Predictor of Outcome in Patients with Gastric Cancer. International Journal of Can-cer, 95, 1-6.
https://doi.org/10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5
|
[21]
|
Chu, Y.Q., Ye, Z.Y., Tao, H.Q., Wang, Y.Y. and Zhao, Z.S. (2008) Relationship between Cell Adhesion Molecules Expression and the Biological Behavior of Gastric Carcinoma. World Journal of Gastroenterology, 14, 1990-1996.
https://doi.org/10.3748/wjg.14.1990
|
[22]
|
Reszegi, A., Tátrai, P., Regős, E., Kovalszky, I. and Baghy, K. (2022) Syndecan-1 in Liver Pathophysiology. American Journal of Physiology-Cell Physiology, 323, C289-C294. https://doi.org/10.1152/ajpcell.00039.2022
|
[23]
|
Matsuda, K., Maruyama, H., Guo, F., et al. (2001) Glypican-1 Is Overexpressed in Human Breast Cancer and Modulates the Mitogenic Effects of Multiple Heparin-Binding Growth Fac-tors in Breast Cancer Cells. Cancer Research, 61, 5562-5569.
|
[24]
|
Lendorf, M.E., Manon-Jensen, T., Kronqvist, P., Multhaupt, H.A. and Couchman, J.R. (2011) Syndecan-1 and Syndecan-4 Are Independent Indicators in Breast Carci-noma. Journal of Histochemistry & Cytochemistry, 59, 615-629.
https://doi.org/10.1369/0022155411405057
|
[25]
|
Loussouarn, D., Campion, L., Sagan, C., et al. (2008) Prognostic Impact of Syndecan-1 Expression in Invasive Ductal Breast Carcinomas. British Journal of Cancer, 98, 1993-1998. https://doi.org/10.1038/sj.bjc.6604400
|
[26]
|
Poblete, C.E., Fulla, J., Gallardo, M., et al. (2014) Increased SNAIL Expression and Low Syndecan Levels Are Associated with High Gleason Grade in Prostate Cancer. International Jour-nal of Oncology, 44, 647-654.
https://doi.org/10.3892/ijo.2014.2254
|
[27]
|
Suhovskih, A.V., Mostovich, L.A., Kunin, I.S., et al. (2013) Proteo-glycan Expression in Normal Human Prostate Tissue and Prostate Cancer. ISRN Oncology, 2013, Article ID: 680136. https://doi.org/10.1155/2013/680136
|
[28]
|
Harada, K., Masuda, S., Hirano, M. and Nakanuma, Y. (2003) Reduced Expression of Syndecan-1 Correlates with Histologic Dedifferentiation, Lymph Node Metastasis, and Poor Prognosis in Intrahepatic Cholangiocarcinoma. Human Pathology, 34, 857-863. https://doi.org/10.1016/S0046-8177(03)00336-8
|
[29]
|
Dieudonné, F.X., Marion, A., Haÿ, E., Marie, P.J. and Mo-drowski, D. (2010) High Wnt Signaling Represses the Proapoptotic Proteoglycan Syndecan-2 in Osteosarcoma Cells. Cancer Research, 70, 5399-5408.
https://doi.org/10.1158/0008-5472.CAN-10-0090
|
[30]
|
Marion, A., Dieudonné, F.X., Patiño-Garcia, A., Lecanda, F., Marie, P.J. and Modrowski, D. (2012) Calpain-6 Is an Endothelin-1 Signaling Dependent Protective Factor in Chemoresistant Osteosarcoma. International Journal of Cancer, 130, 2514-2525. https://doi.org/10.1002/ijc.26246
|
[31]
|
Modrowski, D., Orosco, A., Thévenard, J., Fromigué, O. and Marie, P.J. (2005) Syndecan-2 Overexpression Induces Osteosarcoma Cell Apoptosis: Implication of Syndecan-2 Cytoplasmic Do-main and JNK Signaling. Bone, 37, 180-189.
https://doi.org/10.1016/j.bone.2005.04.010
|
[32]
|
Orosco, A., Fromigué, O., Haÿ, E., Marie, P.J. and Modrowski, D. (2006) Dual Involvement of Protein Kinase C Delta in Apoptosis Induced by Syndecan-2 in Osteoblasts. Journal of Cel-lular Biochemistry, 98, 838-850.
https://doi.org/10.1002/jcb.20826
|
[33]
|
Modrowski, D., Baslé, M., Lomri, A. and Marie, P.J. (2000) Syndecan-2 Is Involved in the Mitogenic Activity and Signaling of Granulocyte-Macrophage Colony-Stimulating Factor in Osteoblasts. Journal of Biological Chemistry, 275, 9178-9185. https://doi.org/10.1074/jbc.275.13.9178
|
[34]
|
Corti, F., Ristori, E., Rivera-Molina, F., et al. (2022) Syndecan-2 Selectively Regulates VEGF-Induced Vascular Permeability. Nature Cardiovascular Research, 1, 518-528. https://doi.org/10.1038/s44161-022-00064-2
|
[35]
|
Gopal, S., Arokiasamy, S., Pataki, C., Whiteford, J.R. and Couchman, J.R. (2021) Syndecan Receptors: Pericellular Regulators in Development and Inflammatory Disease. Open Biology, 11, Article ID: 200377.
https://doi.org/10.1098/rsob.200377
|
[36]
|
Patterson, A.M., Gardner, L., Shaw, J., et al. (2005) Induction of a CXCL8 Binding Site on Endothelial Syndecan-3 in Rheumatoid Synovium. Arthritis & Rheumatology, 52, 2331-2342. https://doi.org/10.1002/art.21222
|
[37]
|
Patterson, A.M., Cartwright, A., David, G., et al. (2008) Differential Ex-pression of Syndecans and Glypicans in Chronically Inflamed Synovium. Annals of Rheumatic Diseases, 67, 592-601. https://doi.org/10.1136/ard.2006.063875
|
[38]
|
Hudák, A., Letoha, A., Vizler, C. and Letoha, T. (2022) Syndecan-3 as a Novel Biomarker in Alzheimer’s Disease. International Journal of Molecular Sciences, 23, Article No. 3407. https://doi.org/10.3390/ijms23063407
|
[39]
|
Wang, J., Chen, P., Hu, B., et al. (2023) Distinct Effects of SDC3 and FGFRL1 on Selective Neurodegeneration in AD and PD. FASEB Journal, 37, e22773. https://doi.org/10.1096/fj.202201359R
|
[40]
|
Labiano, S., Palazon, A. and Melero, I. (2015) Immune Response Regulation in the Tumor Microenvironment by Hypoxia. Seminars in Oncology, 42, 378-386. https://doi.org/10.1053/j.seminoncol.2015.02.009
|
[41]
|
Noman, M.Z., Hasmim, M., Lequeux, A., et al. (2019) Im-proving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells, 8, Article No. 1083.
https://doi.org/10.3390/cells8091083
|
[42]
|
Palazon, A., Goldrath, A.W., Nizet, V. and Johnson, R.S. (2014) HIF Transcription Factors, Inflammation, and Immunity. Immunity, 41, 518-528. https://doi.org/10.1016/j.immuni.2014.09.008
|
[43]
|
Gilkes, D.M., Semenza, G.L. and Wirtz, D. (2014) Hypoxia and the Extracellular Matrix: Drivers of Tumour Metastasis. Nature Reviews Cancer, 14, 430-439. https://doi.org/10.1038/nrc3726
|
[44]
|
Horie, S., Ishii, H. and Kazama, M. (1990) Heparin-Like Glycosaminoglycan Is a Receptor for Antithrombin III-Dependent but Not for Thrombin-Dependent Prostacyclin Production in Human En-dothelial Cells. Thrombosis Research, 59, 895-904. https://doi.org/10.1016/0049-3848(90)90113-Q
|
[45]
|
Hoffmann, J.N., Vollmar, B., Inthorn, D., Schildberg, F.W. and Menger, M.D. (2000) Antithrombin Reduces Leukocyte Adhesion during Chronic Endotoxemia by Modulation of the Cyclooxygenase Pathway. American Journal of Physiology-Cell Physiology, 279, C98-C107. https://doi.org/10.1152/ajpcell.2000.279.1.C98
|
[46]
|
Guo, C., Fan, X., Qiu, H., Xiao, W., Wang, L. and Xu, B. (2015) High-Resolution Probing Heparan Sulfate-Antithrombin Interaction on a Single Endothelial Cell Surface: Sin-gle-Molecule AFM Studies. Physical Chemistry Chemical Physics, 17, 13301-13306. https://doi.org/10.1039/C5CP01305D
|
[47]
|
Bohdan, N., Espín, S., Águila, S., et al. (2016) Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site. PLOS ONE, 11, e0157834. https://doi.org/10.1371/journal.pone.0157834
|
[48]
|
Tanino, Y., Chang, M.Y., Wang, X., et al. (2012) Syndecan-4 Regulates Early Neutrophil Migration and Pulmonary Inflammation in Response to Lipopolysaccharide. American Jour-nal of Respiratory Cell and Molecular Biology, 47, 196-202. https://doi.org/10.1165/rcmb.2011-0294OC
|
[49]
|
Xu, J., Park, P.W., Kheradmand, F. and Corry, D.B. (2005) Endogenous Attenuation of Allergic Lung Inflammation by Syndecan-1. The Journal of Immunology, 174, 5758-5765. https://doi.org/10.4049/jimmunol.174.9.5758
|
[50]
|
Constantinescu, A.A., Vink, H. and Spaan, J.A. (2003) Endo-thelial Cell Glycocalyx Modulates Immobilization of Leukocytes at the Endothelial Surface. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 1541-1547.
https://doi.org/10.1161/01.ATV.0000085630.24353.3D
|
[51]
|
Echtermeyer, F., Bertrand, J., Dreier, R., et al. (2009) Syndecan-4 Regulates ADAMTS-5 Activation and Cartilage Breakdown in Osteoarthritis. Nature Medicine, 15, 1072-1076. https://doi.org/10.1038/nm.1998
|
[52]
|
Korb-Pap, A., Stratis, A., Mühlenberg, K., et al. (2012) Early Structural Changes in Cartilage and Bone Are Required for the Attachment and Invasion of Inflamed Synovial Tissue during Destructive Inflammatory Arthritis. Annals of Rheumatic Diseases, 71, 1004-1011. https://doi.org/10.1136/annrheumdis-2011-200386
|
[53]
|
Zhao, J., Ye, X. and Zhang, Z. (2022) Syndecan-4 Is Cor-related with Disease Activity and Serological Characteristic of Rheumatoid Arthritis. Advances in Rheumatology, 62, Ar-ticle No. 21. https://doi.org/10.1186/s42358-022-00254-3
|
[54]
|
Cao, C., Shi, Y., Zhang, X., et al. (2022) Cholester-ol-Induced LRP3 Downregulation Promotes Cartilage Degeneration in Osteoarthritis by Targeting Syndecan-4. Nature Communications, 13, Article No. 7139.
https://doi.org/10.1038/s41467-022-34830-4
|